MedTrace Logo

Eribulin Mesylate in Treating Patients With Recurrent or Metastatic Salivary Gland Cancer

NCT01613768 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2018-09-28

Study results available
· View outcomes & findings →

Summary

Researchers are doing a research study to examine the use of eribulin (eribulin mesylate) in patients with salivary gland cancer. Researchers want to know if eribulin is safe and effective in treating salivary gland cancer.

Conditions

  • Recurrent Salivary Gland Cancer
  • Stage IVA Salivary Gland Cancer
  • Stage IVB Salivary Gland Cancer
  • Stage IVC Salivary Gland Cancer

Interventions

DRUG

eribulin mesylate

Given IV

Sponsors & Collaborators

Principal Investigators

  • Renato Martins, MD, MPH · Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-05-08
Primary Completion
2017-08-23
Completion
2017-08-23

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01613768 on ClinicalTrials.gov